Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Free Cash Flow (2016 - 2025)

Regenxbio (RGNX) has 12 years of Free Cash Flow data on record, last reported at -$51.3 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 56.78% year-over-year to -$51.3 million; the TTM value through Dec 2025 reached -$124.9 million, up 28.88%, while the annual FY2025 figure was -$124.9 million, 28.88% up from the prior year.
  • Free Cash Flow reached -$51.3 million in Q4 2025 per RGNX's latest filing, up from -$56.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $326.9 million in Q4 2021 and bottomed at -$85.7 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$31.6 million, with a median of -$51.1 million recorded in 2023.
  • The widest YoY moves for Free Cash Flow: up 2485.08% in 2021, down 125.7% in 2021.
  • A 5-year view of Free Cash Flow shows it stood at $326.9 million in 2021, then crashed by 113.72% to -$44.8 million in 2022, then rose by 6.59% to -$41.9 million in 2023, then increased by 21.92% to -$32.7 million in 2024, then crashed by 56.78% to -$51.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$51.3 million in Q4 2025, -$56.5 million in Q3 2025, and -$49.7 million in Q2 2025.